Prima BioMed Ltd (ADR)  

(Public, NASDAQ:PBMD)   Watch this stock  
Find more results for PBMD
+0.03 (3.17%)
Real-time:   2:07PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.09 - 1.17
52 week 0.42 - 6.48
Open 1.09
Vol / Avg. 223,964.00/600,493.00
Mkt cap 74.78M
P/E     -
Div/yield     -
EPS     -
Shares 68.61M
Beta 1.92
Inst. own     -
Feb 29, 2016
Interim 2016 Prima BioMed Ltd Earnings Release (Estimated) Add to calendar
Nov 24, 2015
Prima BioMed Ltd Annual Shareholders Meeting
Nov 12, 2015
Prima BioMed Ltd Annual Shareholders Meeting (Estimated)
Oct 8, 2015
Prima BioMed Ltd Ltd KPI Quarterly Report - September 2015
Sep 9, 2015
Prima BioMed Ltd at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    


Plaza Building, L 12 95 Pitt St
+61-2-92761224 (Phone)
+61-2-85691880 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company's main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response. The Company's product is a T cell immunostimulatory factor (APC activator), IMP321, for cancer chemoimmunotherapy, which has completed Phase II trials. In addition, it has developed infrastructure for a cell-based therapy manufacturing platform and taken CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The Company's other products include IMP731 for autoimmune disease, and IMP701 for cancer and chronic infectious disease.

Officers and directors

Marc Voigt Chief Executive Officer, Executive Director
Bio & Compensation  - Reuters
Sharron Gargosky Chief Technical Officer
Bio & Compensation  - Reuters
Deanne Miller General Counsel, Company Secretary
Bio & Compensation  - Reuters
Bradley J. Monk Member of the Clinical Advisory Board
Bio & Compensation  - Reuters
Lucy H. Turnbull Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Yue-Ling Wong Non-Executive Deputy Chairman of the Board
Bio & Compensation  - Reuters
Russell John Howard Ph.D. Non-Executive Director
Bio & Compensation  - Reuters
Pete A. Meyers Non-Executive Director
Age: 45
Bio & Compensation  - Reuters